There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Hollings Cancer Center, Charleston, South Carolina
Conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Colorectal Cancer Screening in Cystic Fibrosis
Recruiting
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any adenomas, including advanced adenomas and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/24/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/24/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Accellacare Trident Cardiology, Charleston, South Carolina
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of th... Read More
Gender:
All
Ages:
Between 6 months and 5 years
Trial Updated:
05/24/2024
Locations: Coastal Pediatric Associates, Charleston, South Carolina +2 locations
Conditions: SARS-CoV-2
Healing, Equity, Advocacy and Respect for Mamas
Recruiting
The goal of the proposed research is to test the comparative effectiveness of AIM safety bundles for post-partum women delivered in-person vs. via text/phone to improve early detection of and timely care for complications during the first six weeks postpartum for women experiencing significant health disparities.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
05/23/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Postpartum Complication
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/23/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Stroke, PFO - Patent Foramen Ovale
Accelerated iTBS for Post Partum Depression
Recruiting
Study 1: The investigators are studying the feasibility and tolerability of 10x/day intermittent theta burst (excitatory) transcranial magnetic stimulation to the left dorsolateral prefrontal cortex over the course of 6 days for women with post-partum depression. The investigators further aim to characterize the anticipated anti-depressant effect of this treatment paradigm. Study 2: The investigators are studying the feasibility and tolerability of 12 sessions/day of intermittent theta burse (e... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
05/23/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Post Partum Depression
A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Advanced Solid Tumor
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/22/2024
Locations: RH Johnson VA Medical Center, Charleston, South Carolina +1 locations
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Recruiting
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 Period A, participants are placed in 1 of 3 groups, c... Read More
Gender:
All
Ages:
Between 12 years and 63 years
Trial Updated:
05/22/2024
Locations: Medical University of South Carolina /ID# 259828, Charleston, South Carolina
Conditions: Alopecia Areata
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation